Comparative Pharmacology
Head-to-head clinical analysis: EPIPEN E Z PEN versus SUS PHRINE SULFITE FREE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EPIPEN E Z PEN versus SUS PHRINE SULFITE FREE.
EPIPEN E Z PEN vs SUS-PHRINE SULFITE FREE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Epinephrine is a direct-acting sympathomimetic amine that acts on alpha- and beta-adrenergic receptors. Alpha-adrenergic stimulation increases peripheral vascular resistance, reversing hypotension and improving coronary perfusion. Beta-adrenergic stimulation causes bronchodilation, positive inotropy, and chronotropy.
Epinephrine is a sympathomimetic catecholamine that acts as a non-selective agonist at all adrenergic receptors (α1, α2, β1, β2, β3). Its primary therapeutic effects include vasoconstriction (α1-mediated), bronchodilation (β2-mediated), and positive chronotropic/inotropic effects (β1-mediated).
0.3 mg intramuscularly every 5-15 minutes as needed for anaphylaxis. Administer into anterolateral thigh.
0.3-0.5 mg subcutaneously or intramuscularly every 15-20 minutes as needed for anaphylaxis. Maximum single dose: 0.5 mg.
None Documented
None Documented
The terminal elimination half-life of epinephrine is approximately 2-3 minutes when administered intravenously. The short half-life necessitates repeated doses or continuous infusion for sustained effect.
2 minutes (initial rapid phase), terminal half-life approximately 1-2 hours (alpha phase). Clinical context: Very short half-life necessitates continuous infusion for sustained effect.
Epinephrine is rapidly metabolized in the liver and other tissues by catechol-O-methyltransferase (COMT) and monoamine oxidase (MAO). Approximately 80-90% of an intravenous dose is excreted in the urine as inactive metabolites (metanephrine, vanillylmandelic acid, 3,4-dihydroxymandelic acid) with less than 5% excreted unchanged.
Primarily renal excretion of metabolites (vanillylmandelic acid, metanephrine, and other conjugates); less than 2% excreted unchanged. Minimal biliary/fecal elimination.
Category C
Category C
Adrenergic Agonist
Adrenergic Agonist